Experimental β-Cell Senescence Models Link Autophagy Defects to Impaired Insulin Secretion Dynamics

A newly characterized doxorubicin-induced model of pancreatic β-cell senescence links impaired mitochondrial and insulin granule clearance to altered stimulus-secretion coupling, providing a novel research platform for evaluating metabolic rejuvenation therapies.

Researchers from Osaka University Graduate School of Medicine, the University of Toronto, and the National Center for Geriatrics and Gerontology established and characterized an experimental model of pancreatic β-cell senescence using doxorubicin (DOX) on MIN6 cells.

The model was validated via senescence-associated β-galactosidase positivity, upregulation of p16INK4a, p21, and p53, and cell cycle arrest.

Using reporter constructs, researchers demonstrated that senescent β-cells accumulate mitochondria and insulin granules due to impaired autophagy-driven clearance.

Upon glucose stimulation, senescent β-cells exhibited exaggerated mitochondrial hyperpolarization, altered Ca2+ influx, and increased reactive oxygen species production, resulting in a disproportionately enhanced insulin secretion relative to overall reduced storage.

Pancreatic β-cell dysfunction is a central driver of type 2 diabetes, a primary metabolic pathology of aging.

While β-cell senescence has been recognized in age-related diabetes, the precise organelle-level remodeling and secretory dynamics have been difficult to track.

By establishing a reliable, experimentally tractable model connecting DNA damage to defective mitochondrial and granule clearance, this study offers a robust platform for testing pipeline candidates aimed at reversing metabolic senescence.

The study provides a functional assay platform for preclinical drug discovery, enabling high-throughput screens of compounds designed to clear senescent cell burden or restore autophagy in islet cells.

Biotechnology firms advancing therapeutic pipelines targeting metabolic longevity, cell rejuvenation, or selective senolysis can utilize these characterized organelle retention pathways for target validation.

Preclinical validation studies using this model to screen established or experimental senolytic agents and autophagy-inducing compounds to evaluate their capacity to restore normal stimulus-secretion coupling in β-cells.